Access to Gene Therapies: A Geographic Divide
Access to advanced gene therapies is significantly influenced by where patients reside, as highlighted by a patient's struggle and an analysis of Medicaid data. These treatments, which can cost millions of dollars, face substantial challenges in equitable distribution across the U.S. healthcare system.
Patient Case Study: Dustin Vidrine
Dustin Vidrine, 34, from Lafayette, Louisiana, has retinitis pigmentosa, an inherited eye disease leading to vision loss. He became legally blind and sought gene therapy to preserve his vision. While a gene therapy, Luxturna, exists for some mutations, it does not apply to his specific condition.
Vidrine aimed to join a clinical trial for a different therapy, which requires specialized care available in Texas but not in southern Louisiana. His initial attempts to schedule an appointment in Texas were complicated by his UnitedHealthcare insurance plan. UnitedHealthcare later clarified its position.
UnitedHealthcare stated that residency is not a requirement for out-of-state care and confirmed it covers out-of-network providers in specific situations, indicating it is currently working with Vidrine.
Systemic Barriers to Access
Dr. Will Shrank, founder of Aradigm, a company dedicated to expanding gene therapy access, identified significant systemic issues. He noted that the U.S. healthcare system's fragmented nature inherently hinders the equitable delivery of these costly, one-time treatments.
The Centers for Medicare and Medicaid Services (CMS) explained that for dually eligible individuals (Medicare/Medicaid), coverage can depend on network status and service area. Medicaid, being state-based, may require prior authorization for out-of-state non-emergency care. Additional rules also apply for clinical trial participation.
Geographic Disparities in Therapy Provision
An NPR analysis of 2024 Medicaid data revealed significant variations in gene therapy payments across states. States like California, Indiana, Massachusetts, and Texas paid for more therapies, while Nebraska, North Dakota, South Dakota, and Oklahoma paid for relatively few.
Ameet Sarpatwari, a Harvard professor studying drug policy, suggested that states with more academic medical centers tend to offer more gene therapies. He pointed out that while state Medicaid programs should cover out-of-state treatment if local options are unavailable, the data indicates this is not consistently occurring.
"Geographic location is a significant hurdle, with some states having no facilities offering specific gene therapies."
– Sarah Kikkert, American Society of Gene and Cell Therapy
Sarah Kikkert of the American Society of Gene and Cell Therapy confirmed that geographic location is a major barrier. While 44 states have at least one facility, over half of these facilities offer only one type of gene therapy, highlighting the limited availability.
Efforts to Address Disparities
Companies like Aradigm are actively developing solutions for health plans, and the Center for Medicare & Medicaid Innovation is testing models designed to enhance treatment accessibility. Meanwhile, Dustin Vidrine remains in contact with his insurance provider regarding his Texas appointment.